Case Study: Resource Mapping in Malawi
Achieving universal access to HIV treatment requires using the resources available as efficiently as possible. To this end, CHAI supports 10 countries to conduct annual resource mapping. In Malawi, results have informed the allocation of US$300 million to high-impact interventions and increased national ownership of the HIV response. Learn more about CHAI’s work improving efficiency...
Read more
World Hepatitis Day 2015
Viral hepatitis is a major public health problem throughout the world, killing more people every year than HIV.(i) Hepatitis C is a viral disease transmitted through infected bodily fluids and attacks the liver, slowly scarring the organ until the person acquires liver cancer or faces a number of other renal or hepatic conditions that diminish...
Read more
Breakthrough global agreement sharply lowers price of early infant diagnosis of HIV
CHAI and global partners in the Diagnostics Access Initiative have joined with Roche Diagnostics to announce a 35 percent reduction in the price for HIV early infant diagnostic technologies. The new access price is US$9.40 per test, including proprietary reagents and consumables associated with diagnosing HIV in very young children. Learn more here.
Read more
“Big Data” Helping to Inform Big Decisions
CHAI’s Research and Development (R&D) Team works from a unique angle to support CHAI’s ambitions to improve patient outcomes in low- and middle-income countries. In particular, the team works to: 1. Identify, develop, validate, and transfer for manufacture and distribution better and less expensive drug formulations of existing HIV/AIDS, tuberculosis (TB), and malaria medicines; 2....
Read more
ViiV Healthcare and CHAI collaboration delivers second milestone with first filing with the FDA of generic dolutegravir by Aurobindo Pharma for the treatment of HIV
ViiV Healthcare and CHAI collaboration delivers second milestone with first filing with the FDA of generic dolutegravir by Aurobindo Pharma for the treatment of HIV London, May 26, 2015 – ViiV Healthcare, Aurobindo Pharma, and the Clinton Health Access Initiative, Inc. (CHAI) announced today that Aurobindo Pharma has submitted an Abbreviated New Drug Application (ANDA)...
Read more
CHAI and partners announce agreement to help save mothers’ lives
An agreement announced today will reduce the achievable cost per use of the non-pneumatic anti-shock garment (NASG) by over 75 percent and expand access to this innovative new product, which has been shown to safely and effectively reduce mortality due to post-partum hemorrhage, a leading cause of the nearly 290,000 maternal deaths reported annually around the world.
Read more
Donor Disclosure Policy Q&A
Clinton Health Access Initiative, Inc. Donor Disclosure Policy – Q & A April 16, 2015 Q: Why is CHAI’s policy different from the Clinton Foundation’s policy? CHAI is an independent 501c3 charitable organization, separate from the Clinton Foundation. CHAI operates in over 30 countries and has nearly 1,500 employees, over 80 percent of whom are...
Read more
CHAI Family Planning Market Report: May 2015
In 2019, updates to historical datasets were made upon consultation with relevant current suppliers, including the addition of a new supplier’s data. Please find the most up-to-date report here. The 2015 Family Planning Market Report can be found below.
Read more
CHAI and partners expand Hispaniola malaria elimination efforts
The U.S. Centers for Disease Control and Prevention (CDC) is leading a consortium of malaria partners aiming to eliminate indigenous cases of malaria on the island of Hispaniola by 2020.
Read more
CHAI ARV Ceiling Price List: 2014
CHAI supports national governments to expand high-quality care and treatment to people living with HIV/AIDS.
Read more